rosiglitazone has been researched along with Fasting Hypoglycemia in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (66.67) | 29.6817 |
2010's | 5 (27.78) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Hamzah, MF; Muhammad, TST; Noruddin, NAA; Rosman, Z; Salin, NH; Shu-Chien, AC | 1 |
Dangi-Garimella, S | 1 |
Bebakar, WM; Brändle, M; Colagiuri, S; Kamaruddin, NA; Le Thi, TD; Marre, M; Shaw, J; Strand, J; Zdravkovic, M | 1 |
Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
Brath, H; Ludvik, B; Toplak, H; Wascher, T | 1 |
McGill, JB | 1 |
Depaoli, AM; Higgins, LS | 1 |
Endo, S; Fujino, Y; Fujita, Y; Honma, H; Inoue, Y; Onodera, M; Satoh, J | 1 |
Egidi, G; Popert, U | 1 |
Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J | 1 |
Cutson, JJ; Dietz, KR; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Johnson, L; Matsusue, K; Nicol, CJ; Reitman, ML; Vinson, C | 1 |
Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
Cappleman, JM; Hale, PM; Kaye, W; Khutoryansky, N; McGill, J; Raskin, P; Saad, MF | 1 |
Bruce, S; Garber, A; Klein, E; Mohideen, P; Sankoh, S | 1 |
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Gaddi, AV; Ghelfi, M; Piccinni, MN; Salvadeo, S | 1 |
Elias, AN; Lizotte, P | 1 |
Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B | 1 |
Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M | 1 |
3 review(s) available for rosiglitazone and Fasting Hypoglycemia
Article | Year |
---|---|
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Practice Guidelines as Topic; Prognosis; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2009 |
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Pioglitazone; PPAR gamma; Quinolines; Retinoid X Receptors; Rosiglitazone; Sulfonamides; Thiazolidinediones | 2010 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
7 trial(s) available for rosiglitazone and Fasting Hypoglycemia
Article | Year |
---|---|
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States | 2011 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2004 |
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Rosiglitazone; Tablets; Thiazolidinediones; Treatment Outcome | 2006 |
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2006 |
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2008 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
8 other study(ies) available for rosiglitazone and Fasting Hypoglycemia
Article | Year |
---|---|
Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Membrane; Glucose; Hepatocytes; Hypoglycemia; Insulin; Ligands; Mice; Momordica; Muscle Cells; PPAR gamma; Protein Domains; Rosiglitazone; Triterpenes | 2021 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].
Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2009 |
[Detection of glimepiride and rosiglitazone from Chinese dietary supplements].
Topics: Aged; China; Chromatography, Liquid; Dietary Supplements; Drug Overdose; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Rosiglitazone; Sulfonylurea Compounds; Tandem Mass Spectrometry; Thiazolidinediones | 2011 |
[Glycemic control and cardiovascular benefit: what do we know today?].
Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones | 2011 |
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Female; Hypoglycemia; Insulin Resistance; Lipid Metabolism; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; RNA; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2003 |
Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
Topics: Cell Differentiation; Female; Humans; Hypoglycemia; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Peroxisome Proliferator-Activated Receptors; Radionuclide Imaging; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms | 2006 |